This study was designed to show ITGA5 as a therapeutic target in PSCs and to assess the therapeutic potential of the novel peptidomimetic (AV3) in combination with chemotherapy in a PDX pancreatic tumor model. We investigated the prognostic value of ITGA5 in patients with PDAC, and the tissue samples were obtained during 2001 to 2012 from 137 patients with pancreatic adenocarcinoma. In vitro assays (qPCR, Western blot, immunocytochemistry, migration assay, and contraction assays) and in vivo xenograft tumor models (co-injection tumor model and PDX models) were used to investigate ITGA5 as a therapeutic target in PSCs and the efficacy of novel peptidomimetic AV3. Most of the findings were evaluated by more than one method, and experiments were repeated multiple times independently. In vivo experiments were randomized and partly blinded, and the number of samples was calculated using power test considering meaningful differences, % coefficient of variation within the experiment, and a minimum P value of 0.05. Cultured cells or PDX tissues were used for these animal models. All experiments were conducted under the international animal ethical guidelines, which were approved by the animal ethical committee of Utrecht University, The Netherlands.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.